Can denosumab be given every 3 months?  

With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data and giving denosumab every 3 months as well?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Yuma Regional Medical Center Cancer Center
RANKL inhibitors have a shorter half-life and as s...
Sign in or Register to read more